Eli Lilly’s weight-loss drug revenues miss expectations due to lower prices

On an adjusted basis, Lilly earned $3.34 per share for the quarter, compared with analysts’ estimates of $3.02 per share

The company cut its annual adjusted profit forecast to between $20.78 and $22.28 per share from its previous expectation of between $22.50 and $24.00 per share. Picture: Larry Cummins.

Eli Lilly posted better-than-expected quarterly results, although sales of its popular weight-loss drug Zepbound came in slightly below estimates.

The success of Lilly’s diabetes and weight-loss treatments, much of which is manufactured at the company’s facility in Kinsale, has led Eli Lilly to become the world’s most valuable healthcare company, with a market capitalisation of over $800bn (€702.2bn).